US · IMRX
Immuneering Corporation
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 02142
- Website
- immuneering.com
Price · as of 2024-12-31
$5.37
Market cap 181.15M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $6.49 | $21.05 | $4.23 | $0.00 | $1.83 |
| 2022 | $7.53 | $27.86 | $1.90 | $0.00 | $139.71 |
| 2023 | $6.56 | $30.65 | |||
| 2024 | $1.52 |
AI valuation
Our deep-learning model estimates Immuneering Corporation's (IMRX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $5.37
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| IMRX | Immuneering Corporation | $5.37 | 181.15M | — | — | — | — | -0.75 | 1.10 | — | -0.21 | -8.77 | 1.33 | 0.00% | — | — | -92.51% | -682.42% | -78.61% | 0.10 | — | 5.28 | 4.82 | 0.50 | 851.00% | — | 1171.00% | -120.87% | -7.33 | -586.70% | 0.00% | 0.00% | 0.00% | -0.21 | -0.25 | — | -6.82 |
| ARCT | Arcturus Therapeutics Hol… | $8.23 | 233.85M | +247% | -10% | — | +29% | -4.85 | 1.63 | 2.84 | -2.38 | -2.89 | 1.63 | 100.00% | -69.13% | -58.49% | -31.16% | -388.69% | -20.93% | 0.12 | — | 4.67 | 3.68 | 2.69 | 16786.00% | -1227.00% | 18760.00% | -15.37% | -0.91 | -245.39% | 0.00% | 0.00% | 0.00% | -1.93 | -3.05 | 1.33 | 0.78 |
| ASMB | Assembly Biosciences, Inc… | $29.84 | 256.95M | +2,630% | +9,923% | — | — | -1.66 | 2.00 | 2.34 | 0.93 | — | 2.00 | 100.00% | -159.26% | -140.87% | -107.92% | 55.92% | -31.39% | 0.09 | — | 2.42 | 2.35 | 0.78 | -5000.00% | 29816.00% | -32743.00% | -76.60% | -1.07 | 62.97% | 0.00% | 0.00% | 26.59% | 0.93 | 0.83 | -1.48 | -9.57 |
| ENTA | Enanta Pharmaceuticals, I… | $14.30 | 332M | +189% | -59% | — | — | -3.80 | 4.81 | 4.77 | -4.57 | — | 4.81 | 92.98% | -130.65% | -125.36% | -84.63% | -91.13% | -24.91% | 3.11 | -11.11 | 4.21 | 4.03 | -2.38 | -2993.00% | -342.00% | -6674.00% | -10.33% | -0.40 | -35.04% | 0.00% | 0.00% | 6.44% | -3.79 | -10.06 | 4.96 | -1.26 |
| FHTX | Foghorn Therapeutics Inc. | $5.68 | 332.74M | +360% | -68% | — | +572% | -2.86 | -5.45 | 10.98 | -0.43 | — | -5.45 | 100.00% | -454.31% | -383.24% | 141.17% | 39.62% | -30.40% | -0.82 | — | 3.73 | 3.64 | 0.19 | -3248.00% | -3383.00% | -1510.00% | -40.83% | -1.50 | 39.09% | 0.00% | 0.00% | 0.00% | -0.40 | -0.41 | 1.84 | -2.64 |
| HUMA | Humacyte, Inc. | $1.12 | 159.24M | — | — | — | — | -2.46 | -6.95 | — | -2.55 | -13.86 | -6.95 | 0.00% | — | — | 760.17% | 252.76% | -111.77% | -0.31 | -12.33 | 2.40 | 2.25 | 0.21 | 1776.00% | — | 3190.00% | -27.23% | -4.92 | 220.27% | 0.00% | 0.00% | 1.48% | -2.95 | -3.39 | — | -8.31 |
| NAUT | Nautilus Biotechnology, I… | $2.42 | 305.66M | — | — | — | — | -4.96 | 1.87 | — | -4.18 | — | 1.87 | 0.00% | — | — | -32.27% | -69.30% | -27.20% | 0.19 | — | 13.33 | 13.00 | -0.34 | -1607.00% | — | -1517.00% | -17.74% | -6.38 | -53.89% | 0.00% | 0.00% | 0.05% | -3.28 | -4.22 | — | 2.18 |
| PYXS | Pyxis Oncology, Inc. | $1.47 | 91.53M | — | — | — | — | -0.88 | 0.56 | 4.20 | 0.59 | — | 0.57 | 97.06% | -554.07% | -478.95% | -62.75% | -416.82% | -46.74% | 0.17 | — | 7.49 | 7.18 | -0.01 | -2865.00% | — | -2522.00% | -85.42% | -3.26 | -277.36% | 0.00% | 0.00% | 16.14% | 0.44 | 0.67 | -2.41 | -3.02 |
| TNYA | Tenaya Therapeutics, Inc. | $0.56 | 93.6M | — | — | — | — | -0.35 | 0.42 | — | 0.09 | — | 0.42 | 0.00% | — | — | -95.69% | -251.45% | -76.52% | 0.15 | — | 4.22 | 3.85 | -0.09 | -2202.00% | — | -1141.00% | -237.15% | -5.67 | -198.49% | 0.00% | 0.00% | 0.00% | 0.08 | 0.10 | — | -7.83 |
| TRDA | Entrada Therapeutics, Inc… | $11.93 | 455.96M | +114% | -46% | — | +2,115% | -3.36 | 1.58 | 19.01 | -1.67 | — | 1.58 | 83.89% | -621.13% | -565.48% | -39.13% | -244.32% | -31.81% | 0.17 | — | 12.53 | 12.09 | 0.28 | -30655.00% | -8794.00% | 18973.00% | -26.81% | -5.26 | -200.46% | 0.00% | 0.00% | 0.10% | -1.51 | -1.84 | 9.38 | 2.64 |
| ZURA | Zura Bio Limited | $6.62 | 430.45M | — | — | — | — | -1.81 | 0.64 | — | 1.48 | — | 0.64 | 0.00% | — | — | -50.84% | 157.33% | -37.38% | 0.00 | — | 9.16 | 9.04 | 3.20 | -7129.00% | — | 2211.00% | -29.76% | -1.44 | 80.25% | 0.00% | 0.00% | 81.08% | 1.48 | 2.91 | — | 1.74 |
About Immuneering Corporation
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
- CEO
- Benjamin J. Zeskind
- Employees
- 54
- Beta
- 0.46
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $5.37) − 1 = — (DCF, example).